Showing results 1 to 60 of 132
|5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion
|김명욱, 김영배, 김효철, 박준성, 조용관, 주희재, 최진혁, 한상욱
|5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection.
|강석윤, 박준성, 안미선, 이광재, 이순영, 이현우, 정성현, 조용관, 최진혁, 한상욱
|A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma
|A Case of Therapy-Related Acute Leukemia With Mixed Phenotype With BCR-ABL1 After Treatment of Diffuse Large B-Cell Lymphoma
|A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
|A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
|A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
|A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
|A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer
|Acute promyelocytic leukemia with complex translocation t(5;17;15)(q35;q21;q22): case report and review of the literature.
|김현주, 박일중, 박준은, 정현주, 조성란
|Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
|Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
|Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
|강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성
|Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study
|강석윤, 김태환, 안미선, 이현우, 최용원, 최진혁
|Appropriate Number of Adjuvant Chemotherapy Cycles for Patients with Stage 2 or 3 Gastric Cancer After Curative Gastrectomy: A Multicenter Cohort Study
|Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
|Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
|강석윤, 김장희, 박준성, 신승수, 안미선, 이광재, 이현우, 정성현, 최진혁, 한재호
|BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis
|노진, 정성현, 최윤석
|Bilateral primary renal non-Hodgkin's lymphoma presenting with acute renal failure: successful treatment with systemic chemotherapy.
|Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
|Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
|Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
|Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
|Combination versus single-agent as palliative chemotherapy for gastric cancer
|강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁
|Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
|Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.
|Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?
|강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 조용관, 최용원, 최진혁, 한상욱, 한재호
|Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL
|김철호, 신유섭, 이복순, 한재호
|Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia
|강석윤, 김태환, 박준성, 안미선, 이현우, 정성현, 최용원, 최윤석, 최진혁
|Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
|Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
|Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis.
|Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
|Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial
|Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
|Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
|김명욱, 김효철, 이기범, 임호영, 조용관, 주희재, 최진혁
|Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
|김명욱, 김현수, 김효철, 남동기, 이기범, 임호영, 조용관, 주희재, 최진혁
|First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism
|Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
|Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
|Gastric cancer in young patients who underwent curative resection. Comparative study with older patients.
|Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
|Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer
|노오규, 오영택, 유희석, 이은주, 장석준, 전미선, 조오연
|Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Radiologic and clinical factors predictive of survival
|권요한, 김재근, 김진우, 원제환, 조효정, 허지미
|High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy
|강석윤, 김장희, 박준성, 신승수, 안미선, 이현우, 정성현, 최용원, 최진혁, 한재호
|Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy
|Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, her2-negative metastatic breast cancer: Subgroup analyses of kcsg-br15-10 (youngpearl)
|Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
|Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.
|Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
|Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
|강석윤, 박준성, 안미선, 이순영, 이현우, 정성현, 최용원, 최진혁
|Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death
|Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
|강두경, 김구상, 김태희, 임현이
|Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity
|강두경, 강석윤, 김구상, 김태희, 임현이, 정용식
|MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting.
|Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics.
|김유선, 이다겸, 조혜성, 최경숙
|Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites.
|Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
|Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.